LOGO
LOGO

Corporate News

Japan Approves Regeneron's Antibody Cocktail To Treat Mild To Moderate COVID-19

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024

Japan's Ministry of Health, Labour and Welfare has approved Regeneron Pharmaceuticals Inc.'s (REGN) casirivimab and imdevimab antibody cocktail to treat patients with mild to moderate COVID-19.

It marks the first time the antibody cocktail, known as REGEN-COVTM in the U.S. and Ronapreve in other countries, has received a full approval to treat COVID-19, Regeneron said in a statement.

Emergency or temporary pandemic use authorizations are currently in place in more than 20 countries, including in the U.S., European Union, India, Switzerland and Canada.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Business News

Global Economics Weekly Update - Jun 08-12, 2026

June 12, 2026 17:14 ET
Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.